Log in to save to my catalogue

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c9a8bb9c2aac44dba476758c76c4a8d4

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Publication information

Publisher

London: Nature Publishing Group UK

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. This resistance was abrogated by treatment with the F...

Alternative Titles

Full title

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_c9a8bb9c2aac44dba476758c76c4a8d4

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c9a8bb9c2aac44dba476758c76c4a8d4

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-019-09068-2

How to access this item